NJ-BLUE-EARTH
8.7.2024 13:01:26 CEST | Business Wire | Press release
Bracco and Blue Earth Diagnostics Ltd, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the appointment of Marco Campione as its new Chief Executive Officer (CEO), reporting to Bracco Imaging CEO Fulvio Renoldi Bracco. Mr. Campione also joins the Blue Earth Diagnostics Ltd Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Board of Directors. Dr. David Gauden, a co-founder of Blue Earth Diagnostics and with the Company since 2014, assumes the role of full-time CEO of Bracco subsidiary Blue Earth Therapeutics. The changes reflect a carefully planned strategy to drive continued growth, development and opportunity for both companies and Bracco.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240708534807/en/
Marco Campione, Chief Executive Officer, Blue Earth Diagnostics, a Bracco company (Photo: Business Wire)
“I congratulate Marco Campione on this CEO appointment and we look forward to drawing upon his strategic, operational and broad general business expertise as we increase our global leadership throughout the diagnostic radiopharmaceutical industry,” said Fulvio Renoldi Bracco, CEO of Bracco Imaging. “Marco joins the Bracco Group at a transformative point in our evolution, as the company matures, broadens its horizons globally and expands its commercial presence.”
Mr. Renoldi continued, “I also want to take this opportunity to recognize the many contributions of David Gauden in advancing the success of Blue Earth Diagnostics, and I wish him the best of success in now leading Blue Earth Therapeutics as its full-time CEO.”
“I am excited and honored to assume the role of CEO at Blue Earth Diagnostics,” said Mr. Campione. “The Company is a recognized leader throughout the nuclear medicine and oncology communities, having a strong reputation grounded in successful innovation, execution and dedicated service on behalf of patient health. I look forward to applying my experience towards expanding availability of the Company’s PET imaging products for prostate cancer, advancing its development programs in PET neuro-oncology and solid tumors, and in exploring additional opportunities and collaborations.”
Marco Campione brings more than 25 years of experience from GE HealthCare, where he most recently served as Executive Director and Global Head of Contrast Media, General Manager Pharmaceutical Diagnostics North America and President GE HealthCare Inc.
About Blue Earth Diagnostics
Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company’s success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. Blue Earth Diagnostics’ expanding oncology portfolio encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy. For more information, please visit: www.blueearthdiagnostics.com.
About Bracco Imaging
Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions. It offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems and dose-management software. In 2019 Bracco Imaging enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting-edge biotechnology vehicle to develop radiopharmaceutical therapies. Visit: www.braccoimaging.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240708534807/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TestMu AI Introduces DevTools Assertions in Kane CLI, Enabling Browser-Level Validation Through Natural Language16.6.2026 14:30:00 CEST | Press release
New capability allows developers and AI agents to validate network activity, console logs, browser storage, and performance metrics without writing custom scripts TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced DevTools Assertions for Kane CLI, enabling developers and AI agents to validate browser internals using natural language. Traditional browser automation focuses on what users can see: buttons, forms, text, and visual states. However, modern web applications depend heavily on browser activity that remains invisible to users, including network requests, API responses, console logs, cookies, local storage, and performance metrics. With DevTools Assertions, Kane CLI extends browser validation beyond the UI, allowing teams to verify these underlying signals using plain-English objectives. Developers can now write objectives such as: "Click Add to Cart and assert the request to /api/cart returned status 200." "Run the
Allegro DVT’s Pulsar Decoder IP Adds Support for AV2 Video Codec16.6.2026 14:30:00 CEST | Press release
Allegro DVT, the leader in Semiconductor Video IPs and Video Compliance Tools, announces the availability its real-time AV2 Decoder IP integrated into its Pulsar™ D400 Series Multi-Standard Decoding IP. This milestone is a follow-up to the company’s announcement in September 2026 that underscored its plans to develop solutions for the emerging AV2 ecosystem spanning both video compliance tools and semiconductor IPs. As global demand for high-quality streaming continues to accelerate, AV2 is emerging as the next major open, royalty-free video compression standard. Developed by the Alliance for Open Media (AOM), AV2 represents a generational leap in video coding, designed to address evolving streaming requirements and enable new media experiences. Building on the success of AV1, AV2 introduces capabilities that support advanced applications such as immersive content (AR/VR), multi-view and split-screen streaming, and improved screen content handling, while operating across a wider range
Sai Life Sciences Achieves EcoVadis Platinum Rating, Joining the Top 1% of Companies Assessed Worldwide16.6.2026 14:27:00 CEST | Press release
Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development, and manufacturing organizations (CRDMOs) has secured the EcoVadis Platinum Rating 2026, placing it among the top 1% of companies assessed worldwide for sustainability performance. With an overall score of 87/100 and a 99th percentile ranking, Sai Life Sciences has achieved Platinum Medal in ‘Manufacture of Basic Pharmaceutical Products and Pharmaceutical Preparations’ category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616260047/en/ Sai Life Sciences achieves EcoVadis Platinum Rating, joining the top 1% of companies assessed worldwide Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “Sustainability is becoming one of the defining measures of excellence in our industry. The ability to innovate, grow and create impact must be matched by an equal commitment
Plaud Scales From $1M to $100M ARR Within Two Years, Bringing AI Beyond the Screen for Professionals16.6.2026 14:25:00 CEST | Press release
Among the fastest-known AI companies, Plaud stands out as a rare hardware-enabled AI company in a cohort dominated by software-only players. Plaud, the company building real-world AI interface for professionals, today announced it has scaled from $1M to $100M in ARR within two years, placing it among the fastest AI companies globally to reach the milestone. Plaud is the only hardware-enabled AI company in a cohort otherwise dominated by software-only players, and now serves more than 2 million professionals across 170+ countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616945160/en/ The fastest AI growth stories have, until now, belonged almost entirely to software-native companies: AI coding tools, enterprise workflow agents, and other SaaS products scaling behind screens and keyboards. Plaud's growth represents a different model — recurring AI software scaled through a real-world physical interface, with devices
Rehlko Integrates WB Power Services into its UK and EMEA Platform, Expanding Lifecycle Capabilities for Mission-Critical Power16.6.2026 14:00:00 CEST | Press release
Rehlko, a global energy resilience leader delivering innovative solutions across industrial energy systems, powertrain technologies, and home energy applications, today announced that its UK business, formerly WB Power Services, has been fully brought onto the Rehlko platform, strengthening the company’s UK and Europe, Middle East, and Africa (EMEA) operating model and expanding its ability to deliver end-to-end lifecycle solutions for mission-critical power applications. The move aligns the former WB Power Services’ long-established UK capabilities – including engineering, installation, commissioning, and long-term service – with Rehlko’s broader platform. It represents an important step in scaling consistent, high-quality delivery across priority markets as demand accelerates in data centers and other mission-critical environments. Customers increasingly require partners that can deliver reliable, repeatable solutions across the full project lifecycle and over long operating horizons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom